6,108 research outputs found

    Letter from Cy Donner to Michi Weglyn, June 2, 1967

    No full text
    A letter from Cy Donner to Michi Weglyn encouraging her to come out to California to talk to producers about two shows called "Youthquake" and "Pretty Talk".These materials are from box 73 and 74 of the Frank Chin Papers. The Frank Chin Papers contain personal and professional correspondence between Frank Chin and Michi Weglyn relating to particular projects on which either author was working as well as files related to the Day of Remembrance Tribute to Michi Weglyn

    Effects of polysaccharides (AP) treatment (given subcutaneously once daily) on white blood cell (WBC) number in cyclophosphamide (CY)-treated mice

    No full text
    <p><b>Copyright information:</b></p><p>Taken from "Polysaccharides from the root of protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice"</p><p>International Journal of Medical Sciences 2006;3(1):1-6.</p><p>Published online 1 Jan 2006</p><p>PMCID:PMC1332197.</p><p>© Ivyspring International Publisher. This is an open access article. Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited.</p> CY was given subcutaneously (200 mg/kg) at day 0 and day 7 and AP was also injected subcutaneously once daily during the 14-day experimental period. Nor: Normal untreated group; NS: normal saline plus CY-treated group; AP5: AP 5 mg/kg plus CY-treated group, AP10: AP 10 mg/kg plus CY-treated group, AP25: AP 25 mg/kg plus CY-treated group, respectively.

    Triterpenoid saponins from Ilex mamillata CY Wu ex CJ Tseng

    No full text
    Two new triterpenoid saponins, ilemaminosides A and B (1 and 2) along with six known saponins (3-8) were isolated from 70% ethanolic extract of the leaves of Ilex mamillata C.Y. Wu ex C.J. Tseng. The new saponins were characterised as 3-O-alpha-L-arabinopyranosyl-ilexgenin B (1) and 3-O-beta-D-glucopyranosyl-(1 -&gt; 3)-alpha-L-arabinopyranosyl-ilexgenin B (2). The structures of compounds 1 and 2 were elucidated on the basis of the chemical and spectroscopic methods, and the structures of known compounds were identified by comparison of their spectroscopic data with those reported in the literature. The compounds showed inhibitory activities in anti-inflammatory assay in vitro with IC50 values in the range 25.37-38.33 mu gmL(-1).http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309287500006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Chemistry, AppliedChemistry, MedicinalSCI(E)5ARTICLE211991-19952

    Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia

    Full text link
    The choice of conditioning regimen before allogeneic stem cell transplantation (SCT) in patients with acute lymphoblastic leukemia (ALL) is important. We retrospectively compared outcomes of medium-dose VP-16/cyclophosphamide/total body irradiation (VP/CY/TBI) regimen and CY/TBI. Five hundred and twenty-nine patients (VP/CY/TBI: n = 35, CY/TBI: n = 494) who met all of the following criteria were compared: first time for SCT, aged 15-59 years; first or second complete remission at SCT; bone marrow or peripheral blood as stem cell source; and HLA phenotypically matched donor. Median age of the patients was 34 years, and patients who received VP/CY/TBI were younger (28 years vs. 34 years, P = 0.02). Cumulative incidences of relapse and non-relapse mortality (NRM) were higher for patients who received CY/TBI (P = 0.01 for relapse, P < 0.01 for NRM). After a median follow-up period of 36.9 months, 5-year overall survival (OS) rates were 82.2% in the VP/CY/TBI group and 55.2% in the CY/TBI group. OS, and disease-free survival (DFS) in the VP/CY/TBI group were shown to be significantly better by multivariate analysis [hazard ratio: 0.21 (95% confidence interval: 0.06-0.49) for DFS, hazard ratio: 0.25 (95% confidence interval: 0.08-0.59) for OS]. VP/CY/TBI was associated with a lower relapse rate and no increase in NRM, resulting in better survival than that in CY/TBI for adult ALL patients
    corecore